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Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer for which treatment options often result
in incomplete therapeutic efficacy and long-term side-effects. Interleukin 7 (IL-7) and its receptor IL-7Rα promote T-ALL
development and mutational activation of IL-7Rα associates with very high risk in relapsed disease. Using combinatorial
phage-display libraries and antibody reformatting, we generated a fully human IgG1 monoclonal antibody (named B12)
against both wild-type and mutant human IL-7Rα, predicted to form a stable complex with IL-7Rα at a different site from
IL-7. B12 impairs IL-7/IL-7R-mediated signaling, sensitizes T-ALL cells to treatment with dexamethasone and can induce
cell death per se. The antibody also promotes antibody-dependent natural killer-mediated leukemia cytotoxicity in vitro and
delays T-cell leukemia development in vivo, reducing tumor burden and promoting mouse survival. B12 is rapidly
internalized and traffics to the lysosome, rendering it an attractive vehicle for targeted intracellular delivery of cytotoxic
cargo. Consequently, we engineered a B12–MMAE antibody–drug conjugate and provide proof-of-concept evidence that it
has increased leukemia cell killing abilities as compared with the naked antibody. Our studies serve as a stepping stone for
the development of novel targeted therapies in T-ALL and other diseases where IL-7Rα has a pathological role.
Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an
aggressive hematological cancer that results from the
transformation of thymic T-cell precursors, accounting for
10–15% of pediatric, and 20–25% of adult, ALL cases.
Although treatment outcome has dramatically improved
throughout the years, this success has been achieved using
intensive chemotherapy that often leads to long-term severe
side-effects. Moreover, more than half of the adult, and up
to 30% of childhood, T-ALL cases relapse [1]. Thus, there
is a pressing need for the development of more selective,
safer, and efficient treatments.
Interleukin 7 (IL-7), a cytokine produced in the thymus,
bone marrow, and other tissues, and its receptor (IL-7R, a
heterodimer of IL-7Rα and γc) are essential for normal
lymphoid development [2]. However, the IL-7/ IL-7R axis
can also play a significant role in leukemogenesis. High IL-
7R expression in murine thymocytes associates with pro-
liferation and leukemogenesis [3], and IL-7 can act as a
lymphoid oncogene in the mouse [4, 5]. In agreement, IL-7
accelerates human T-ALL development in vivo [6].
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3 Departamento de Quiḿica, Universidad de La Rioja, Centro de
Investigacio ́n en Sińtesis Quiḿica, 26006 Logroño, Spain
4 Philochem AG, Libernstrasse 3, Otelfingen, Switzerland
5 Department of Chemistry and Applied Biosciences, Swiss Federal
Institute of Technology (ETH Zürich), Vladimir-Prelog-Weg 4,
Zürich, Switzerland
6 Department of Chemistry, University of Cambridge, Lensfield
Road, CB2 1EW Cambridge, UK
Supplementary information The online version of this article (https://
doi.org/10.1038/s41375-019-0434-8) contains supplementary
material, which is available to authorized users.
12
34
56
78
90
()
;,:
12
34
56
78
90
();
,:
Moreover, studies in vitro showed that leukemia blasts from
a majority of the patients (~ 70%) display IL-7R and that
IL-7 promotes their survival and proliferation [5, 7–9].
Notably, ~ 10% of pediatric T-ALL patients display IL-7Rα
gain-of-function mutations, which lead to constitutive acti-
vation of downstream signaling and subsequent promotion
of cell transformation and tumorigenesis [10], associating
with very poor prognosis in relapsed patients [11]. At the
molecular level, IL-7 stimulation and IL-7R mutational
activation promote T-ALL cell cycle progression and via-
bility by activating oncogenic pathways such as PI3K/Akt/
mTOR and JAK/STAT [12–14]. In addition, IL-7 stimula-
tion of T-ALL cells interferes with drug-induced apoptosis
and cell cycle arrest induced by rapamycin [15], pre-
dnisolone [16], dexamethasone, and doxorubicin [17],
whereas mutant IL-7R-mediated signaling contributes to
resistance to glucocorticoids [18]. Overall, these findings
indicate that biopharmaceuticals targeting the IL-7/IL-7Rα
axis may benefit a large fraction of T-ALL patients (70–
80% of the cases), including those with ultra-high risk
relapsed disease.
Antibody therapies have become the strategy of choice
for the treatment of various forms of cancer [19, 20]. Sev-
eral antibody products have received marketing authoriza-
tion for the treatment of hematological malignancies,
including against CD20, CD38, and CD52. The approval of
brentuximab vedotin (an antibody–drug conjugate against
CD30) for the treatment of certain forms of Hodgkin's
lymphoma and anaplastic large cell lymphoma, and of bli-
natumomab (a bispecific antibody recognizing CD19 and
CD3) for philadelphia-negative relapsed/refractory ALL,
confirms a growing interest in antibody-based therapies to
treat blood cancers [21]. Fully human monoclonal anti-
bodies are particularly attractive, as these products should
display reduced immunogenicity in patients as compared
with antibodies of rodent origin.
Here, we developed and characterized a fully human
monoclonal antibody against IL-7Rα, providing clear proof-
of-concept for the development of antibody-based treat-
ments for T-ALL and other cancers relying on IL-7/IL-7R-
mediated signals.
Materials and methods
Phage-display and antibody selection
Biotinylated IL-7Rα-ECD was immobilized onto Streptavidin-
coated strips (Roche) at a final concentration of 250 nM in
phosphate-buffered saline (PBS). Selections were performed
with two Phage-Display libraries, namely ETH2Gold and
PhiloDiamond [22, 23], following an established protocol [22].
Soluble antibody fragments were detected using enzyme-linked
immunosorbent assay after several rounds of panning. Selected
single-chain variable fragments (scFv) were Sanger-sequenced
and clones with intact sequence were expressed in large scale
in Escherichia coli TG1 strain.
Antibody cloning, expression, and characterization
scFv antibodies were expressed in the TG1 strain with IPTG
induction at 30 °C and purified from the bacterial super-
natant by affinity chromatography using Protein A-
Sepharose (Sino Biological) followed by size-exclusion
chromatography (ÄKTA FPLC GE Healthcare, Superdex
75 column). The scFv fragment of clone B12 was refor-
matted to IgG1 by step-wise cloning giving rise to
pMM137-IgG(B12). IgG(B12) was routinely expressed in
suspension-adapted mammalian Chinese Hamster Ovary
(CHO) cells (Invitrogen) and purified using protein A-
sepharose and size-exclusion chromatography (Superdex
200 column), as previously described [24].
Surface plasmon resonance spectroscopy
Affinity measurements of the purified antibody fragments
were performed by surface plasmon resonance spectroscopy
using BIAcore 3000 (BIAcore AB). Binding kinetics was
analyzed in real-time on CM5 microsensor chip, coated
with IL-7Rα recombinant protein, resulting in 3000
response units of coating. The reference flow was left
uncoated to facilitate background subtraction. Freshly pre-
pared monomeric fractions of scFv(B12) and IgG(B12)
were used immediately after size-exclusion chromatography
for BIAcore analysis, to minimize avidity effects from
diabody or aggregate formation. Binding constants were
calculated using BIAevaluation software (version 3.2).
Generation of IL-7Rα antibody–drug conjugate
The purified Ig(B12) was conjugated with MMAE using a
protease-cleavable valine–citruline linker with a carbonyl
acrylic acid head-group. In brief, interchain disulfide bonds
of a full-length IgG(B12) were reduced using excess
amounts of DTT and reacted with 60 equivalents of car-
bonyl acrylic acid–valine–citruline–MMAE molecule [25].
The reaction was stirred at 37 °C for 8–10 h. The antibody–
drug conjugate was then purified using a desalting column
and concentrated using Vivaspin devices (GE Healthcare).
The average drug-to-antibody ratio was 4:1 as determined
by native mass spectrometry.
3D modeling of B12-IL-7Rα interaction
A homology model of B12 antibody was generated through
SWISS-MODEL platform [26]. Then, 0.5 µs molecular
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dynamics (MD) simulations were run to obtain an equili-
brated structure, as described in the Supplementary Meth-
ods. Docking calculations were performed with PatchDock
Server and FireDock [27] between B12 and unglycosylated
human IL-7Rα (IL-7Rα, pdb ID: 3DI2) to obtain the
complex structure. The best solutions are shown in
Table S1. The solution with the lowest binding energy was
then subjected to 0.5 µs MD simulations.
Cells
Primary human T-ALL cells were collected from peripheral
blood or bone marrow of patients at diagnosis [28]. We
established the primary-like IL-7-dependent cell line TAIL7
[29]. Human TAIL7, HPB-ALL, DND4.1, MOLT4,
TALL1, and Jurkat cell lines, and murine Ba/F3 and D1 cell
lines transduced with mutant or wild-type IL-7R, were
routinely cultured at 37 °C with 5% CO2 in RPMI-1640
medium supplemented with 10% (vol/vol) fetal bovine
serum and 2 mM L-glutamine, plus IL-7 when necessary.
Primary T-ALL cells and normal human thymocytes were
obtained after informed consent and Institutional Review
Board approval. Culture experiments were performed with
or without 50 ng/ml recombinant human IL-7 (Peprotech).
Flow cytometry
Binding of B12 to native IL-7Rα expressed at the surface of
indicated cells was analyzed by flow cytometry. Cells were
incubated with B12 or isotype control at 4 °C for 30 min,
washed with ice-cold PBS and the primary antibody
detected using Goat alexa 647-conjugated anti-human (H+
L) antibody (ThermoFischer Scientific). Cell viability was
determined by forward scatter/side scatter distribution, and
by Annexin V (eBioscience) and 7AAD (BD Bioscience)
staining. Samples were acquired using FACS Fortessa I/II
(BD Bioscience) and analyzed using FlowJo (Tree Star).
Immunoblotting
After the indicated conditions and time points, cell lysates
were prepared and equal amounts of protein (50 µg/sample)
were analyzed by 12% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE), transferred
onto nitrocellulose membranes, and immunoblotted with the
indicated antibodies: pSTAT5 (Y694/Y699) (Millipore),
pAKT (S473), pERK1/2 (T202/Y204), pS6 (S235/S236)
(Cell Signaling Technology), and actin (Santa Cruz Bio-
technology). Detection was performed by incubation with
horseradish peroxidase-conjugated anti-mouse (Promega),
anti-rabbit (Promega), or anti-goat (Santa Cruz Bio-
technology) immunoglobulin (IgG; 1:5000 dilution), as
appropriate and developed by chemiluminescence.
ADCC in vitro assay
Antibody-dependent cell-mediated cytotoxicity (ADCC)
activity was determined by measuring lactate dehy-
drogenase (LDH) release using Cytotoxicity Detection
KitPLUS (Roche). In brief, T-ALL patient-derived xeno-
graft (PDX) target cells (104) were incubated for 30 min
with 10 μg/ml B12 or recombinant human IgG1 Fc (BioX)
as isotype control. Human NK effector cells isolated from
healthy donors were added at the indicated effector-to-target
(E:T) ratio. After 4 h of incubation, reaction mixture was
added to the samples and LDH release measured using a
Molecular Devices VersaMax ELISA reader. The percen-
tage of cytotoxicity was determined as percent lysis=
(effector+ target mix−effector cell alone)−target cell
alone/lysed targets-targets alone ×100.
Confocal microscopy
Antibody colocalization studies were performed by
confocal microscopy analysis in HPB-ALL cells, as
previously described [30]. In brief, cells were incubated
with B12 for 30–45 min, at 4 °C, washed, re-suspended
in PBS and incubated with secondary anti-human IgG
(H+ L)-Alexa 647 antibody (Invitrogen) for 30 min at
4 °C. Cells were then carefully washed with ice-cold
PBS and stimulated with or without 50 ng/ml IL-7 for 30
min at 37 °C. Cells were washed, fixed with ice-cold
methanol for 2–3 min at − 20 °C, permeabilized and
washed with PBS plus 0.05% tween, and incubated for 1
h at room temperature in permeabilization buffer with
antibodies against: clathrin heavy-chain (X22-Alexa
Fluor 555), EEA-1 (EPR4245-Alexa-647) and LAMP-2
(Alexa Fluor 555; all from ThermoFisher Scientific),
followed by 4′,6-diamidino-2-phenylindole nuclear
staining. Image acquisition was performed with the
pinhole aperture set to 1 Airy Unit for the highest
wavelength (633 nm) and adjusted for the lower wave-
lengths to maintain the same optical slice thickness for
all channels. Up to 10 different fields of view with ~80
cells per field of view were collected for quantification.
Percent c-localization was determined by counting the
fraction of cells showing at least one colocalization event
(minimum 3 × 3 pixels) between fluorophores from cells
with intact nuclei and presenting both fluorophores.
In vivo studies with D1 IL-7Rα mutant-expressing
leukemia T cells
All protocols and animal procedures were approved by
institutional Animal Ethics committee of Instituto de Med-
icina Molecular and followed the recommendations for care
and use of laboratory animals by European commission and
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Portuguese authorities. Rag1−/− mice were obtained from
Charles River Laboratories. All mice were 8–12 weeks old
at the start of experiments. Green fluorescent protein
(GFP positive D1mutP2 cells (5 × 106) were injected intra-
venously in the tail (200 μl per injection) into Rag1−/−
mice. Antibody treatment (250 μg/injection) started either 1
or 7 days post engraftment, at the indicated frequency. Mice
were either analyzed for survival or killed on day 15 for
comparison of leukemia burden, in which case organs were
collected for post-mortem analysis by flow cytometry and
histology, as described [31]. In some cases, to identify NK
and macrophages, respectively, organ single-cell suspen-
sions were stained with antibodies against CD56 or CD11b
(eBiosciences). Tumor burden was determined by the fre-
quency of GFP-positive cells in the different organs. All the
samples were acquired and analyzed using FACS Fortessa
(Becton Dickinson) and FlowJo (Tree Star).
Statistical analysis
Data were analyzed using GraphPad Prism (version 6.01;
GraphPad software). Statistical analysis was performed
using Student’s t test or Mann–Whitney test, with Bonfer-
roni post tests; Log-rank or Gehan-Brislow-Wilcoxon tests;
or two-way ANOVA, as appropriate. Differences were
considered significant for p < 0.05.
Results
Isolation of anti-CD127 antibodies from a synthetic
antibody phage-display library
To generate an antibody against the human IL-7Rα subunit
(CD127) using phage-display technology, we first biotiny-
lated the lysine residues of a recombinant product corre-
sponding to the extracellular portion of the protein. Because
the protein was produced in mammalian cells and thus was
heavily glycosylated, the efficiency of biotinylation was
confirmed using a band-shift assay, rather than by mass-
spectrometry. Incubation of biotinylated extracellular-
domain of IL-7Rα with avidin led to the formation of
complexes, which are stable in SDS-PAGE, whereas
unbiotinylated IL-7Rα did not shift (Supplemental
Figure S1).
Monoclonal antibodies specific to IL-7Rα, in scFv for-
mat, were isolated using both ETH2Gold and PHILODia-
mond libraries [22, 23]. After three rounds of selection,
each of the libraries gave multiple ELISA-positive clones.
Most of these clones were further characterized by DNA
sequencing, to exclude repetitive clones. We chose the B12
clone (Figure S1) for further analysis, owing to its char-
acteristics in ELISA and binding in a BIAcore-based
screening assay. scFv(B12) was purified to homogeneity
and analyzed by size-exclusion chromatography, SDS-
PAGE, and ELISA, confirming the presence of a protein of
the expected size and with IL-7Rα-binding capacity
(Fig. 1a–c). The real-time binding kinetics of scFv(B12)
towards IL-7Rα immobilized on CM5 chip were analyzed
by BIAcore, revealing a dissociation kinetics constant (Kd)
of 40.8( ± 17.5) nM, with kon= 3.5( ± 1.2) × 10−5 M −1 and
koff= 1.2( ± 0.6) × 10−3 s−1 (Fig. 1d).
We next reformatted scFv(B12) into full-length human
IgG1, using an expression vector for production in CHO
cells. Characterization of the purified IgG(B12), henceforth
referred to as B12, revealed a lower apparent Kd value of
6.311( ± 4.4) nM, with kon= 1.5( ± 0.56) × 105 M s−1 and
koff= 8.3 ( ± 3.11) × 10−5 s−1 in BIAcore experiments,
owing to the bivalent nature of the antibody (Fig. 1e–h).
Modeling and MD simulations predict stable B12
binding to human IL-7Rα in a different site from IL-7
Next, we sought to predict the region where B12 binds to
IL-7Rα. We first generated a homology model of B12
antibody through the SWISS-MODEL platform [26] and
then ran 0.5 µs MD simulations to obtain an equilibrated
structure. The amino acids that constitute the CDR of the
antibody are all located in the same region of the protein,
validating our 3D B12 model. We then conducted docking
calculations between the modeled B12 and unglycosylated
human IL-7Rα ectodomain (pdb ID: 3DI2) to obtain the
structure of the complex, as described in the Methods. Our
simulations indicate that the complex is stable, and the
binding site is different from that of human IL-7 (Fig. 1i).
Although IL-7 is positioned at the elbow region connecting
the D1 and D2 domains of IL-7Rα (shown with a black
arrow in Fig. 1i) [32], B12 is located on the opposite side.
The interface B12/IL-7Rα largely comprises hydrophobic
and van der Waals interactions, although a few inter-
molecular hydrogen bonds exist in the binding interface
(Figure S2).
B12 recognizes both wild-type and human IL-7Rα
Using Ba/F3 cells ectopically expressing either human or
mouse IL-7Rα we found that B12 recognizes specifically
the human receptor and does not cross-react with the mouse
(Fig. 2a). Furthermore, B12 recognizes both the wild-type
and different mutant forms of the receptor (Table S2), as
demonstrated in Ba/F3 cells (Fig. 2a), T-ALL cell lines
(Fig. 2b) and diagnostic T-ALL patient samples (Fig. 2c).
As expected, B12 showed minimal or no binding to T-ALL
cell lines known to be IL-7R-low/negative, such as Jurkat or
TALL1 (Fig. 2b). The antibody also recognized IL-7Rα in
human thymocytes (Figure S3).
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B12 inhibits both IL-7-dependent and mutant-
dependent IL-7R-mediated signaling and induces
leukemia cell death
Because IL-7/IL-7R-mediated signaling was shown to
promote T-ALL cell survival and proliferation in vitro
[33] and expansion in vivo [12], we next assessed whether
B12 was able to inhibit signal transduction downstream
from the receptor and thereby affect cell survival. B12
clearly downregulated IL-7- (Fig. 3a, b) and mutant IL-
7R- (Fig. 3c, d) dependent signaling. However, it only
induced cell death in some of the cell lines (Fig. 3). This
may reflect the lack of IL-7-dependence in HPB-ALL
cells (Fig. 3b) or the relatively mild inhibitory effect in
D1 cells (Fig. 3d), as opposed to cell lines in which the
antibody had a strong negative effect and that are well-
known to depend on IL-7 signaling, as is the case of
TAIL7 [33], or displaying endogenous IL-7R mutation, as
is the case of DND41 [12].
B12 enhances NK-mediated T-ALL cytotoxicity
To investigate whether IL-7R-expressing cells that were are
not sensitive to B12 alone can be targeted by ADCC, we co-
cultured NK cells with an IL-7R-expressing PDX T-ALL
sample in the presence or absence of B12. We found that
Fig. 1 Characterization of the B12 antibody in scFv and IgG format. a
Schematic domain structure of B12 in scFv format (left), corre-
sponding to a molecular weight of 25 kDa, as shown in SDS-PAGE
(right) in both reducing (R) and non-reducing (NR) conditions, and
monomeric scFv molecules were separated from dimers by b size-
exclusion chromatography (S75 column). c Specific binding of the
antibody to biotinylated-ECD of IL-7Rα is shown by enriched ELISA
signal as compared with control streptavidin. d Binding kinetics were
performed by SPR technology on a BIAcore machine using CM5
microsensor chip. e Schematic domain structure of B12 reformatted
into IgG (left), expressed in mammalian CHO cells with a molecular
mass of 150 kDa (right) and purified by f size-exclusion chromato-
graphy (S200 column). g Improved ELISA signal toward IL-7Rα and
h increased SPR signal as compared to the scFv c, d). i Representative
snapshot from 0.5 μs MD simulations in explicit water. The amino
acids that constitute the CDR of the antibody are in magenta. A movie
of the MD simulations can be found in the online Supplementary
Information
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B12 had a striking effect in promoting the anti-leukemic
activity of NK cells (Fig. 4).
B12 delays tumor development in vivo
Given the ability of B12 to eliminate leukemia cells
in vitro either directly or by promoting the cytotoxic
activity of NK cells, we then evaluated the impact of the
antibody on leukemia growth in vivo. First, we tested a
minimal residual disease-like model of aggressive T-cell
leukemia by starting antibody administration 1 day after
cell transplantation (Fig. 5a), when leukemia cells are not
yet detectable in the blood [34]. At day 15, mice were
killed and organ infiltration analyzed. B12 had a major
effect on leukemia expansion, strikingly decreasing
involvement in the peripheral blood, bone marrow,
spleen, lung, kidney, and, to a lesser degree, in the liver
(Fig. 5b and S4). In agreement with the diminished fre-
quency of malignant cells in the spleen, B12 reversed
splenomegaly (Fig. 5c). As B12 did not kill IL-7R mutant-
expressing D1 cells in vitro (Fig. 3d), these effects were
likely mediated by an ADCC effect in vivo, possibly via
NK cells (Fig. 5d) and/or macrophages (Fig. 5e). Despite
the striking differences in organ infiltration at day 15, the
disease eventually progressed even in the presence of
B12. Nonetheless treatment with the antibody sig-
nificantly prolonged survival of the mice (Fig. 5f). To test
the effect of B12 on full blown leukemia, we started B12
administration at day 7 (Fig. 5g), when D1 cells are easily
detected in the blood. Again, B12 significantly prolonged
mouse survival (Fig. 5h).
Results in D1 cells were recapitulated using human T-
ALL cells. We transplanted HPB-ALL cells sub-
cutaneously into recipient mice and started treatment
when tumor masses were clearly detectable. Mice were
killed when tumors reached ~ 800 mm3. B12 significantly
delayed tumor growth, prolonging mouse survival (Fig-
ure S5a). We also transplanted a PDX sample intrave-
nously into NOD/SCID mice and started treatment at
6 weeks, when human CD45+ cells were detectable in
the blood ( > 3%). Although in this case B12 did not have
an effect on survival, it clearly decreased leukemia cell
Fig. 2 B12 recognizes both the wild-type and gain-of-function mutant
forms of the human IL-7Rα. Cells were incubated with 125 mM (18 μg/
mL) B12 and an anti-human IgG alexa 647 secondary antibody and
analyzed by flow cytometry: a Ba/F3 cells transduced with either wild-
type (wt) or mutant (mut) versions of the mouse or human IL-7Rα. b
T-ALL cell lines with different levels of IL-7Rα expression: low/
negative (Jurkat, TALL1), intermediate (MOLT4), high (HPB-ALL,
IL-7-deprived TAIL7), all of which are IL-7R wild-type; and DND4.1
(high levels of mutant IL-7Rα). c Two primary T-ALL patient sam-
ples, either mutant (Patient 1) or wild-type (Patient 2). Red histograms:
B12, Blue histograms: secondary antibody only; gray-filled histo-
grams: unstained cells
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frequency in the blood (Figure S5b) and the relative levels
of T-ALL cells negatively correlated with the frequency
of NK cells in the blood (Figure S5c).
B12 cooperates with dexamethasone in inducing
leukemia cell death
Combined chemotherapy, involving the administration of
corticosteroids (dexamethasone or prednisolone) and other
drugs, is the mainstay in T-ALL treatment. To have an initial
understanding of whether B12 could be potentially integrated
into current clinical protocols, we cultured T-ALL cells in the
presence of dexamethasone alone or in combination with B12.
We found that B12 augmented cell death in combination with
dexamethasone both in dexamethasone-resistant HPB-ALL
cells (Fig. 6a) and in a dexamethasone-sensitive PDX sample
we analyzed (Fig. 6b). These results indicate that B12 may
potentiate the effect of corticosteroids in eliminating T-ALL
cells and provide proof-of-concept for the combination of anti-
IL-7R antibodies with current chemotherapeutic protocols.
B12 is rapidly internalized and traffics to the
lysosome
Current antibody-based anticancer therapies include the use of
antibody–drug conjugates (ADCs). These may be particularly
Fig. 4 B12 promotes antibody-dependent cell-mediated cytotoxicity
in vitro. a IL-7R-expressing patient-derived xenograft (PDX) T-ALL-5
cells were cultured with freshly isolated NK cells in the presence or
absence of 70 nM (10 μg/mL) of B12. The percentage of cytotoxicity
was measured as described in the “Materials and Methods”
Fig. 3 B12 impacts on IL-7/IL-7R-mediated signaling and cell viabi-
lity. a IL-7 starved TAIL7 cells were incubated with 125 nM (18 μg/
mL) of B12 and 50 ng/ml of IL-7 together for 120 min at 37 °C.
Signaling pathway activation was analyzed by immunoblot using the
indicated phospho-specific antibodies (left). Viability was assessed at
120 h (right). b Serum starved HPB-ALL cells were treated in a similar
manner. Effects on viability were recorded at 120 h. c IL-7R mutant
DND4.1 cells and d D1 cells stably transduced with mutant IL-7Rα
(D1mutP2) were treated with B12 and cell survival was analyzed at
120 h. Statistical analysis was performed using two-tailed unpaired
t test with Welch´s correction (**** p < 0.0001, *** p < 0.001, ** p <
0.01, * p < 0.05). Values indicate the mean and SEM of three repli-
cates. In all experiments an irrelevant IgG isotype was used as negative
control
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useful in patients whose malignant cells may be refractory to
B12 alone and/or in which an ADCC response may be
impaired. To understand whether B12 displays appropriate
characteristics for cargo intracellular delivery we analyzed
B12 internalization and trafficking. We found that, contrary to
a commercial anti-IL-7Rα antibody, B12 is rapidly
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internalized (Fig. 7a), and that IL-7 appears to accelerate B12
internalization (Fig. 7b). Upon internalization, B12 apparently
follows the same intracellular route as IL-7Rα [30], trafficking
via clathrin-coated pits (Fig. 7c) to the early-endosome
(Fig. 7d) and then the lysosome (Fig. 7e). These features
suggest that, if engineered into an ADC, B12 should appro-
priately deliver its cargo into target cells [35].
B12-mono-methyl auristatin E antibody–drug
conjugate kills primary and patient-derived xenograft
T-ALL cells more efficiently than naked B12
Site-specific drug conjugation of B12 was carried out by
reducing interchain disulfide bonds and reacting the thiol
group of free cysteine with a Michael acceptor (carbonyl
acrylic derivate) linked to a cleavable linker (valine–
citrulline) and a cytotoxic drug (MMAE) [25]. Using this
strategy, we generated the ADC B12–MMAE with an
average antibody:drug ratio of ~ 4 (Fig. 8a). B12–MMAE
was characterized using native mass-spectrometry wherein
the unmodified antibody had a mass of 142,909 Da and,
upon conjugation with the drug linker moiety, led to a
heterogenous mixture of ADC with mass corresponding to
various drug-to-antibody ratios (Figure S6a–c). The ADC
retained its binding capacity toward human IL-7Rα (Fig-
ure S6d). We then tested B12–MMAE in the cell lines that
were refractory to B12 alone in vitro. The ADC sig-
nificantly promoted cell death in both HPB-ALL and
mutant IL-7Rα-expressing D1 cells, contrary to the anti-
body alone (Fig. 8b, c). Importantly, the B12–MMAE had
only a minor impact on parental D1 cells, which do not
express the human IL-7Rα (Fig. 8c), indicating that the
effects of the ADC owing to unspecific toxicity from
MMAE are minimal. We then tested primary T-ALL cells
(Fig. 8d) and PDX samples (Fig. 8e), consistently observing
a higher effect of the ADC as compared with B12 alone.
Discussion
Around 70–80% of T-ALL patients present with blasts dis-
playing IL-7Rα and benefit from signals from IL-7 and/or from
receptor mutational activation [10, 12, 33]. A clear majority of
T-ALL patients may therefore benefit from the introduction of
anti-IL-7R therapies into clinical protocols. Signaling-specific
small-molecule inhibitors targeting IL-7R-dependent signaling
effectors, such as JAK1/JAK3, PI3K/Akt/mTOR, or Bcl-2 may
be a valid option [10, 13, 14, 18, 36–41].
Fig. 5 B12 decreases tumor burden and delays T-cell leukemia pro-
gression in vivo. a Treatment and analysis scheme. Rag1−/− mice
(females, n= 5 per group) were injected with 5 × 106 D1mutP2 cells
via lateral tail vein injection. A day later mice were randomly dis-
tributed and injected with 250 μg B12 via the same route. PBS was
used as the vehicle control. Injections were administered every 7 days.
At day 15, a group of mice were killed and tumor burden in various
organs was analyzed, while in another group treatment continued and
survival was monitored. b Percentage of leukemic cells in the indi-
cated organs was analyzed using flow cytometry, wherein the per-
centage of GFP-positive leukemia cells within the live cell population
was considered as the leukemia burden. c Analysis of spleen size.
Frequency of d NK and e macrophage cell infiltration into the indi-
cated organs was analyzed by flow cytometry. Statistical analysis was
performed by unpaired t test (***p < 0.001, **p < 0.01,
*p < 0.05). f Kaplan–Meier survival curves of mice treated with
vehicle (median survival 16 days) or B12 (median survival 21 days).
Statistical analysis was performed using the Log-Rank (Mantel–Cox)
test. g Experimental scheme for treatment starting at day 7 post-
transplantation, when leukemia cells are already clearly detected in the
blood. h Kaplan–Meier survival curves of mice treated with vehicle
(median survival 17 days) or B12 (median survival 19 days). Statistical
analysis was performed using the Log-Rank (Mantel–Cox) test
Fig. 6 B12 cooperates with dexamethasone in inducing leukemia cell
death in vitro. a HPB-ALL and b PDX 203 cells were cultured in
regular medium and treated with the indicated concentration of dex-
amethasone and 125 nM (18 μg/ml) B12 for 72 h. Cell viability was
determined by Annexin V/7AAD staining and data were analyzed by
flow cytometry. Graphics represent the mean and SEM of triplicates
normalized to untreated cells. Statistical analysis was done using
unpaired t test (*p < 0.05, **p < 0.01)
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Here, we explored alternative, antibody-based strategies
to directly target the IL-7R in leukemia cells. There is a
rising interest in the potential of anti-IL-7Rα antibodies for
treatment of autoimmune, chronic inflammatory diseases,
and, more recently, also leukemia [42–54]. However, with
few exceptions [55], the studies published so far have
essentially reported the testing of anti-mouse antibodies in
the context of murine models of disease (e.g., type 1 dia-
betes, multiple sclerosis, rheumatoid arthritis, colitis, sys-
temic lupus erythematosus, or Sjögren’s syndrome) and thus
are clinically inconsequential for humans. In contrast, we
generated a fully human antibody, B12, recognizing human
IL-7Rα both in the wild-type form and in different gain-of-
function mutated variants that drive T-ALL. B12 impairs IL-
7R-mediated signaling and is able to promote T-ALL cell
death in vitro and delay leukemia progression in vivo,
demonstrating obvious pre-clinical value. Consequently,
B12 (or further engineered versions of it) can translate
directly into clinical applications in T-ALL. Moreover, B12
or other antibodies such as those described in the accom-
panying paper by Durum and collaborators, can become
valid tools in the clinical arsenal against other cancers,
especially B-ALL but also chronic lymphocytic leukemia,
other hematological malignancies and even solid tumors
with ectopic expression of IL-7R, such as breast and lung
cancer, where IL-7 and its receptor have been implicated
[56–59]. Evidently, these antibodies may as well prove of
use in autoimmune and chronic inflammatory conditions.
Fig. 7 B12 gets rapidly internalized via clathrin-coated pits and traffics
into early endosomes and lysosomes. a HPB-ALL cells were treated
with 125 nM (18 μg/mL) B12, for the indicated time points at 37 °C
and surface-bound B12 was analyzed by flow cytometry, as described
in “Materials and methods”. Relative signal of B12 bound to IL-7Rα at
the cell surface for each time point was calculated as the geometric
mean intensity of fluorescence normalized to time 0. A commercially
available anti-IL-7Rα from R&D was used for comparison. b HPB-
ALL cells were cultured in the presence or absence of IL-7 (50 ng/mL)
with B12, for the indicated time points. a, b Data represent the mean
from at least two independent experiments. c Analysis of B12 colo-
calization with clathrin was performed by confocal microscopy. HPB-
ALL cells were plated on poly-D-lysine coverslips, incubated with B12
at 4 °C for 45 min and subsequently with secondary anti-human IgG
Alexa 647 (red). After the incubation with B12, cells were shifted to
37 °C to let the internalization happen. Clathrin-coated pits were
detected after 30 min of incubation, by permeabilizing the cells and
staining with anti-clathrin-alexa 568 (green) while the nuclei was
stained with DAPI. Images were acquired using LSM 880 and the
representative picture is a maximum intensity projection of a Z-stack
image, 63× objective. For analysis, at least 10 fields of images were
analyzed, each image having ~ 100 cells in the frame. Percent of cells
with internalization were analyzed by normalizing the cells with
colocalized (yellow) spots to the total cells having both the fluor-
ophores. d B12 localization in early endosomes was detected after 30
min of incubation at 37 °C, using an anti-EEA-1-alexa 555 antibody,
and trafficking to lysosomes after 60 min e was detected using an anti-
LAMP-2-alexa 488 antibody. Statistical analysis was performed using
unpaired t test (***p < 0.001, **p < 0.01, *p < 0.05)
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B12 displays several characteristics that deserve con-
sideration. First, B12 cooperates with dexamethasone in
inducing leukemia cell death in vitro, not only in
dexamethasone-sensitive T-ALL cells but also in a
dexamethasone-resistant cell line. Patients with IL7R
mutations were recently shown to have very high risk in
Fig. 8 B12–drug conjugate
enhances the cytotoxic effect of
the native antibody. a Antibody
in its native form was reduced
using 30 equivalents DTT for 3
h at 37 °C in PBS, to reduce the
interchain disulfide bonds. The
reduced cysteines were then
reacted with 60 equivalents of
carbonyl acrylic acid–valine-
citrulline-monomethyl auristatin
E (compound A) for up to 24 h
at 37 °C. The average Drug-to-
Antibody ratio (DAR) was 4.
b HPB-ALL cells, c D1mutP2
and control D1 parental cells,
d primary T-ALL cells collected
from diagnostic patients, and
e PDX samples were treated
with B12 or B12–drug conjugate
at the indicated concentrations.
Cell death was analyzed after 72
h of culture, using Annexin V/
7AAD staining and data was
analyzed by flow cytometry.
Percentage of live cells was
calculated by normalizing to the
untreated cells
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relapsed disease [11]. This may, in part, relate to the fact
that gain-of-function mutations in the IL-7R signaling
pathway confer resistance to glucocorticoids [18]. As such,
anti-IL-7R antibody-based therapies may be particularly
appealing to prevent or manage relapse in T-ALL.
Second, although B12 recognizes IL-7Rα not only in
malignant cells but also in normal thymocytes, the effect on
thymocyte viability appears to be minimal. The reason for
this is not obvious. It may relate to the different ways in
which the signaling is wired downstream from the IL-7R in
normal versus malignant cells [56]. However, the ability of
B12 to induce T-ALL cell death is heterogeneous and only
in some cases does B12 kill leukemia cells per se. This
happens despite the fact that B12 generally impairs IL-7R-
mediated signaling. Intriguingly, we found that the T-ALL
cell lines most sensitive to B12 were the ones in which clear
signaling inhibition (of STAT5, Akt, and Erk) was paralleled
by upregulated phospho-S6. The ability of antibodies to
modulate signaling in ways that are not strictly agonistic or
antagonistic is of biological and potential clinical importance
[60]. These considerations apart, the fact that healthy thy-
mocytes are less affected by antibody treatment than T-ALL
cells could be a positive feature in the clinic. Also note-
worthy is the fact that hematopoietic stem cells do not
express or rely on IL-7R-mediated signaling. Thus, even if
particular normal hematopoietic subpopulations are elimi-
nated by the antibody, the system should be able to recover
after treatment termination and disease eradication.
Finally, contrary to the antibodies in the accompanying
paper, which do not appear to internalize (making them
especially adequate for ADCC), B12 showed remarkably fast
internalization kinetics, with substantial trafficking into lyso-
somes. Although B12 also demonstrated the ability to induce
ADCC in vitro, and likely in vivo, these features are notably
useful for optimal intracellular cargo delivery in ADCs.
Overall, our studies and those of Durum and collabora-
tors, demonstrate the feasibility, and the underlying promise
for further developments, of antibody-based strategies tar-
geting IL-7R for the treatment of T-ALL and other patho-
logical conditions in which IL-7 and IL-7R have a role.
Acknowledgements This work was supported by UID/BIM/50005/
2019, project funded by Fundação para a Ciência e a Tecnologia
(FCT)/Ministério da Ciência, Technologia e Ensino Superior
(MCTES) through Fundos do Orçamento de Estado; and by the
FAPESP/20015/2014 grant from FCT, and the consolidator grant from
the European Research Council (ERC) CoG-648455 (to JTB). We
thank the EU for further funding (Marie Sklodowska-Curie ITN
Protein Conjugates grant to GJLB and PhD studentship to PA, GA
No. 675007); and also acknowledge ETH Zürich, the Swiss National
Science Foundation (Grant Nr. 310030B_163479/1) and the ERC
Advanced Grant Nr. 670603 “ZAUBERKUGEL” (to DN). JTB, RF,
and GJLB (IF/00624/2015) are FCT investigators. GJLB is a Royal
Society University Research Fellow (UF110046 and URF\R\180019)
and the recipient of an ERC Starting Grant (grant agreement Nr.
676832). MO is a LisbonBioMed student and received an FCT PhD
fellowship. We thank Dr. Di Wu and professor Dame Carol Robinson
for native mass-spectrometry analysis of the ADC. We especially
thank the generosity of patients and their families, and the collabora-
tion of all the team from the Pediatrics Service of Instituto Português
de Oncologia de Lisboa.
Author contributions PA designed and performed experiments, ana-
lyzed, and interpreted data, and wrote the manuscript; RF, JH, SR, MO
designed, and performed experiments, analyzed, and interpreted data;
TC performed histological analyses; AG helped with initial antibody
discovery; MM designed and developed the plasmid construct for IgG
production in mammalian cells; FC performed the 3D-modeling stu-
dies; SKD contributed to the supervision of the ADCC experiments
and provided critical suggestions to the study; DN designed research,
analyzed, and interpreted data, and supervised the antibody generation
and reformatting; GJLB designed research, analyzed, and interpreted
data, supervised the antibody production, modeling and generation of
ADCs, and wrote the manuscript; JTB designed research, analyzed,
and interpreted data, supervised the molecular and cellular in vitro and
in vivo biological characterization experiments, and wrote the manu-
script; JTB and GJLB jointly coordinated the complete study. All
authors critically read and contributed to the final version of the
manuscript.
Compliance with ethical standards
Conflict of interest The authors have no conflicts of interest to declare.
Publisher’s note: Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Pui C-H, Jeha S. New therapeutic strategies for the treatment of
acute lymphoblastic leukaemia. Nat Rev Drug Discov.
2007;6:149–65.
2. Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R
expression in T-B+NK+ severe combined immunodeficiency.
Nat Genet. 1998;20:394–7.
3. Cao X, Shores EW, Hu-Li J, Anver MR, Kelsail BL, Russell SM,
et al. Defective lymphoid development in mice lacking expression
of the common cytokine receptor γ chain. Immunity. 1995;2:223–
38.
4. Rich BE, Campos-Torres J, Tepper RI, Moreadith RW, Leder P.
Cutaneous lymphoproliferation and lymphomas in interleukin 7
transgenic mice. J Exp Med. 1993;177:305–16.
5. Abraham N, Ma MC, Snow JW, Miners MJ, Herndier BG,
Goldsmith MA. Haploinsufficiency identifies STAT5 as a modi-
fier of IL-7-induced lymphomas. Oncogene. 2005;24:5252–7.
P. Akkapeddi et al.
6. Silva A, Laranjeira ABA, Martins LR, Cardoso BA, Demengeot J,
Andrés Yunes J, et al. IL-7 contributes to the progression of
human T-cell acute lymphoblastic leukemias. Cancer Res.
2011;71:4780–9.
7. Laouar Y, Crispe IN, Flavell RA. Overexpression of IL-7Ra
provides a competitive advantage during early T-cell develop-
ment. Blood. 2004;103:1985–94.
8. Scupoli MT, Perbellini O, Krampera M, Vinante F, Cioffi F,
Pizzolo G. Interleukin 7 requirement for survival of T-cell acute
lymphoblastic leukemia and human thymocytes on bone marrow
stroma. Haematologica. 2007;92:264–6.
9. Touw I, Pouwels K, van Agthoven T, van Gurp R, Budel L,
Hoogerbrugge H, et al. Interleukin-7 is a growth factor of pre-
cursor B and T acute lymphoblastic leukemia. Blood. 1990;75:
2097–101.
10. Zenatti PP, Ribeiro D, Li W, Zuurbier L, Silva MC, Paganin M,
et al. Oncogenic IL7R gain-of-function mutations in childhood T-
cell acute lymphoblastic leukemia. Nat Genet. 2011;43:932–9.
11. Richter-Pechańska P, Kunz JB, Hof J, Zimmermann M, Rausch T,
Bandapalli OR, et al. Identification of a genetically defined ultra-
high-risk group in relapsed pediatric T-lymphoblastic leukemia.
Blood Cancer J. 2017;7:e523.
12. Barata JT, Keenan TD, Silva A, Nadler LM, Boussiotis VA,
Cardoso AA. Common γ chain-signaling cytokines promote
proliferation of T-cell lymphoblastic leukemia. Haematologica.
2004;89:1459–67.
13. Barata JT, Silva A, Brandao JG, Nadler LM, Cardoso AA,
Boussiotis VA. Activation of PI3K is indispensable for interleukin
7-mediated viability, proliferation, glucose use, and growth of T
cell acute lymphoblastic leukemia cells. J Exp Med. 2004;200:
659–69.
14. Canté-Barrett K, Spijkers-Hagelstein JAP, Buijs-Gladdines
JGCAM, Uitdehaag JCM, Smits WK, Van Der Zwet J, et al.
MEK and PI3K-AKT inhibitors synergistically block activated
IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
Leukemia. 2016;30:1832–43.
15. Brown VI, Fang J, Alcorn K, Barr R, Kim JM, Wasserman R,
et al. Rapamycin is active against B-precursor leukemia in vitro
and in vivo, an effect that is modulated by IL-7-mediated sig-
naling. Proc Natl Acad Sci USA. 2003;100:15113–8.
16. Duyn AEJ, Kaspers GJL, Pieters R, Van Zantwijk CH, Broekema
GJ, Hählen K, et al. Effects of interleukin 3, interleukin 7, and B-
cell growth factor on proliferation and drug resistance in vitro in
childhood acute lymphoblastic leukemia. Ann Hematol.
1999;78:163–71.
17. Wuchter C, Ruppert V, Schrappe M, Dörken B, Ludwig WD,
Karawajew L. In vitro susceptibility to dexamethasone- and
doxorubicin-induced apoptotic cell death in context of maturation
stage, responsiveness to interleukin 7, and early cytoreduction
in vivo in childhood T-cell acute lymphoblastic leukemia. Blood.
2002;99:4109–15.
18. Li Y, Buijs-Gladdines JGCAM, Canté-Barrett K, Stubbs AP,
Vroegindeweij EM, Smits WK, et al. IL-7 receptor mutations and
steroid resistance in pediatric T cell acute lymphoblastic leukemia:
a genome sequencing study. PLoS Med. 2016;13:e1002200.
19. Weiner GJ. Building better monoclonal antibody-based ther-
apeutics. Nat Rev Cancer. 2015;15:361–70.
20. Walsh G. Biopharmaceutical benchmarks 2014. Nat Biotechnol.
2014;32:992–1000.
21. Ayyar BV, Arora S, O’Kennedy R. Coming-of-age of antibodies
in cancer therapeutics. Trends Pharmacol Sci. 2016;37:1009–28.
22. Weber M, Bujak E, Putelli A, Villa A, Matasci M, Gualandi L,
et al. A highly functional synthetic phage display library con-
taining over 40 billion human antibody clones. PLoS ONE.
2014;9:e100000.
23. Silacci M, Brack S, Schirru G, Mårlind J, Ettorre A, Merlo A,
et al. Design, construction, and characterization of a large syn-
thetic human antibody phage display library. Proteomics.
2005;5:2340–50.
24. List T, Neri D. Biodistribution studies with tumor-targeting bis-
pecific antibodies reveal selective accumulation at the tumor site.
Mabs. 2012;4:775–83.
25. Bernardim B, Cal PMSD, Matos MJ, Oliveira BL, Martínez-Saéz
N, Albuquerque IS, et al. Stoichiometric and irreversible cysteine-
selective protein modification using carbonylacrylic reagents. Nat
Commun. 2016;7:13128–37.
26. Bienert S, Waterhouse A, De Beer TAP, Tauriello G, Studer G,
Bordoli L, et al. The SWISS-MODEL repository-new features and
functionality. Nucleic Acids Res. 2017;45:D313–9.
27. Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ.
PatchDock and SymmDock: Servers for rigid and symmetric
docking. Nucleic Acids Res. 2005;33:W363–7.
28. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis
M, et al. PTEN posttranslational inactivation and hyperactivation
of the PI3K/Akt pathway sustain primary T cell leukemia viabi-
lity. J Clin Invest. 2008;118:3762–74.
29. Barata JT, Boussiotis VA, Yunes JA, Ferrando, Moreau LA,
Veiga JP, et al. IL-7-dependent human leukemia T-cell line as a
valuable tool for drug discovery in T-ALL. Blood.
2004;103:1891–900.
30. Henriques CM, Rino J, Nibbs RJ, Graham GJ, Barata JT. IL-7
induces rapid clathrin-mediated internalization and JAK3-
dependent degradation of IL-7Rα in T cells. Blood. 2010;115:
3269–77.
31. Correia NC, Fragoso R, Carvalho T, Enguita FJ, Barata JT. MiR-
146b negatively regulates migration and delays progression of T-
cell acute lymphoblastic leukemia. Sci Rep. 2016;6:31894–904.
32. McElroy CA, Dohm JA, Walsh STR. Structural and biophysical
studies of the human IL-7/IL-7Ralpha complex. Structure.
2009;17:54–65.
33. Karawajew L, Ruppert V, Wuchter C, Kösser A, Schrappe M,
Dörken B, et al. Inhibition of in vitro spontaneous apoptosis by
IL-7 correlates with bcl-2 up-regulation, cortical/mature immu-
nophenotype, and better early cytoreduction of childhood T-cell
acute lymphoblastic leukemia. Blood. 2000;96:297–306.
34. Bride KL, Vincent TL, Im S-Y, Aplenc R, Barrett DM, Carroll
WL, et al. Preclinical efficacy of daratumumab in T-cell acute
lymphoblastic leukemia. Blood. 2018;131:995–9.
35. Carter PJ. Potent antibody therapeutics by design. Nat Rev
Immunol. 2006;6:343–57.
36. Senkevitch E, Li W, Hixon JA, Andrews C, Cramer SD, Pauly
GT, et al. Inhibiting Janus Kinase 1 and BCL-2 to treat T cell
acute lymphoblastic leukemia with IL7-Rα mutations. Oncotarget.
2018;9:22605–17.
37. Shochat C, Tal N, Bandapalli OR, Palmi C, Ganmore I, te Kronnie
G, et al. Gain-of-function mutations in interleukin-7 receptor-α
(IL7R) in childhood acute lymphoblastic leukemias. J Exp Med.
2011;208:901–8.
38. Melão A, Spit M, Cardoso BA, Barata JT. Optimal interleukin-7
receptor-mediated signaling, cell cycle progression and viability
of t-cell acute lymphoblastic leukemia cells rely on casein kinase 2
activity. Haematologica. 2016;101:1368–79.
39. Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A,
Selvanathan A, et al. Efficacy of JAK/STAT pathway inhibition in
murine xenograft models of early T-cell precursor (ETP) acute
lymphoblastic leukemia. Blood. 2015;125:1759–67.
40. Delgado-Martin C, Meyer LK, Huang BJ, Shimano KA, Zinter
MS, Nguyen JV, et al. JAK/STAT pathway inhibition overcomes
IL7-induced glucocorticoid resistance in a subset of human T-cell
acute lymphoblastic leukemias. Leukemia. 2017;31:2568–76.
A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic. . .
41. Treanor LM, Zhou S, Janke L, Churchman ML, Ma Z, Lu T, et al.
Interleukin-7 receptor mutants initiate early T cell precursor leu-
kemia in murine thymocyte progenitors with multipotent potential.
J Exp Med. 2014;211:701–13.
42. Okada E, Yamazaki M, Tanabe M, Takeuchi T, Nanno M, Osh-
ima S, et al. IL-7 exacerbates chronic colitis with expansion of
memory IL-7Rhigh CD4+mucosal T cells in mice. Am J Physiol
Gastrointest Liver Physiol. 2005;288:G745–54.
43. Hartgring SAY, Willis CR, Alcorn D, Nelson LJ, Bijlsma JWJ,
Lafeber FPJG, et al. Blockade of the interleukin-7 receptor inhi-
bits collagen-induced arthritis and is associated with reduction of
T cell activity and proinflammatory mediators. Arthritis Rheum.
2010;62:2716–25.
44. Mai HLe, Boeffard F, Longis J, Danger R, Martinet B, Haspot F,
et al. IL-7 receptor blockade following T cell depletion promotes
long-term allograft survival. J Clin Invest. 2014;124:1723–33.
45. Lawson BR, Gonzalez-Quintial R, Eleftheriadis T, Farrar MA,
Miller SD, Sauer K, et al. Interleukin-7 is required for CD4+ T
cell activation and autoimmune neuroinflammation. Clin Immu-
nol. 2015;161:260–9.
46. Yasunaga M, Manabe S, Matsumura Y. Immunoregulation by IL-
7R-targeting antibody-drug conjugates: overcoming steroid-
resistance in cancer and autoimmune disease. Sci Rep. 2017;
7:1–14.
47. van Roon JAG, Hartgring SAY, Wenting-van Wijk M, Jacobs
KMG, Tak P-P, Bijlsma JWJ, et al. Persistence of interleukin 7
activity and levels on tumour necrosis factor alpha blockade
in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:
664–9.
48. Hartgring SAY, Van Roon JAG, Van WijkMW, Jacobs KMG,
Jahangier ZN, Willis CR, et al. Elevated expression of interleukin-
7 receptor in inflamed joints mediates interleukin-7-induced
immune activation in rheumatoid arthritis. Arthritis Rheum.
2009;60:2595–605.
49. Gonzalez-Quintial R, Lawson BR, Scatizzi JC, Craft J, Kono DH,
Baccala R, et al. Systemic autoimmunity and lymphoproliferation
are associated with excess IL-7 and inhibited by IL-7Rα blockade.
PLoS ONE. 2011;6:e27528–540.
50. Lee L-F, Axtell R, Tu GH, Logronio K, Dilley J, Yu J, et al. IL-7
promotes TH1 cell differentiation and its level in serum predicts
response to interferon-β in multiple sclerosis. Sci Transl Med.
2011;3:93RA68.
51. Hartgring SAY, Willis CR, Bijlsma JWJ, Lafeber FPJG, van Roon
JAG. Interleukin-7-aggravated joint inflammation and tissue
destruction in collagen-induced arthritis is associated with T-cell
and B-cell activation. Arthritis Res Ther. 2012;14:R137.
52. Lee L-F, Logronio K, Tu GH, Zhai W, Ni I, Mei L, et al. Anti-IL-
7 receptor- reverses established type 1 diabetes in nonobese dia-
betic mice by modulating effector T-cell function. Proc Natl Acad
Sci. 2012;109:12674–9.
53. Penaranda C, Kuswanto W, Hofmann J, Kenefeck R, Narendran
P, Walker LSK, et al. IL-7 receptor blockade reverses autoimmune
diabetes by promoting inhibition of effector/memory T cells. Proc
Natl Acad Sci. 2012;109:12668–73.
54. Jin JO, Kawai T, Cha S, Yu Q. Interleukin-7 enhances the Th1
response to promote the development of Sjögren’s syndrome-like
autoimmune exocrinopathy in mice. Arthritis Rheum.
2013;65:2132–42.
55. Dunham J, Lee LF, van Driel N, Laman JD, Ni I, Zhai W, et al.
Blockade of CD127 exerts a dichotomous clinical effect in mar-
moset experimental autoimmune encephalomyelitis. J Neu-
roimmune Pharmacol. 2016;11:73–83.
56. Oliveira ML, Akkapeddi P, Ribeiro D, Melão A, Barata JT. IL-
7R-mediated signaling in T-cell acute lymphoblastic leukemia: an
update. Adv Biol Regul. 2018;71:88–96.
57. Al-Rawi MAA, Rmali K, Watkins G, Mansel RE, Jiang WG.
Aberrant expression of interleukin-7 (IL-7) and its signalling
complex in human breast cancer. Eur J Cancer. 2004;40:494–502.
58. Boesch M, Onder L, Cheng HW, Novkovic M, Mörbe U, Sopper
S, et al. Interleukin 7-expressing fibroblasts promote breast cancer
growth through sustenance of tumor cell stemness. Oncoimmu-
nology. 2018;7:e1414129.
59. Suzuki K, Kadota K, Sima CS, Nitadori JI, Rusch VW, Travis
WD, et al. Clinical impact of immune microenvironment in stage i
lung adenocarcinoma: Tumor interleukin-12 receptor β2 (IL-12R
b2), IL-7R, and stromal FoxP3/CD3 ratio are independent pre-
dictors of recurrence. J Clin Oncol. 2013;31:490–8.
60. Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong
WJ, et al. Tuning cytokine receptor signaling by re-orienting
dimer geometry with surrogate ligands. Cell. 2015;160:1196–208.
P. Akkapeddi et al.
